The aim of this study was to verify the usefulness of HIF-1α, GLUT-1, and CAIX, determined immunohistochemically in primary tumor and analyzed together with other clinical parameters, in predicting prognosis and planning tailored treatment of endometrial cancer patients. This evidence concerns the gene SLC2A1 and endometrial cancer.